在文献中所提到的28种报告和数据系统（RADS）中，我们确定了15个可以用于磁共振成像（MRI）的RADS。没有使用基于钆的造影剂（GBCA）进行检查有其优点，但通常需要使用GBCA来实现早期和准确的诊断。本综述的目的是总结GBCA在MRI RADS中的当前作用。这一概述表明，大多数当前的RADS中都需要使用GBCA，并且预计在癌症患者进行的大多数MRI检查中都会使用GBCA。在PI-RADS和VI-RADS中，动态对比增强是正确计算得分所必需的，尽管科学证据将来可能会导致在这两个RADS中避免使用GBCA。在Bone-RADS中，可能需要对比增强才能分类一个侵袭性病变。在全身MRI数据集上的RADS评分（MET-RADS-P、MY-RADS和ONCO-RADS）、NS-RADS和Node-RADS中，GBCA的使用是可选的，因为MRI具有固有的高对比度分辨率。需要进行未来的研究来评估高T1弛豫度GBCA对RADS评分的影响。©2023年，作者。

Among the 28 reporting and data systems (RADS) available in the literature, we identified 15 RADS that can be used in Magnetic Resonance Imaging (MRI). Performing examinations without using gadolinium-based contrast agents (GBCA) has benefits, but GBCA administration is often required to achieve an early and accurate diagnosis. The aim of the present review is to summarize the current role of GBCA in MRI RADS. This overview suggests that GBCA are today required in most of the current RADS and are expected to be used in most MRIs performed in patients with cancer. Dynamic contrast enhancement is required for correct scores calculation in PI-RADS and VI-RADS, although scientific evidence may lead in the future to avoid the GBCA administration in these two RADS. In Bone-RADS, contrast enhancement can be required to classify an aggressive lesion. In RADS scoring on whole body-MRI datasets (MET-RADS-P, MY-RADS and ONCO-RADS), in NS-RADS and in Node-RADS, GBCA administration is optional thanks to the intrinsic high contrast resolution of MRI. Future studies are needed to evaluate the impact of the high T1 relaxivity GBCA on the assignment of RADS scores.© 2023. The Author(s).